Results of prospective clinical trials on reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) in chronic lymphocytic leukemia (CLL).
| . | Dreger et al16 . | Sorror et al15 . | Brown et al24 . | Khouri et al25 . | Schetelig et al13 . | Delgado et al36 . |
|---|---|---|---|---|---|---|
| aFludarabine, cyclophosphamide, plus anti-thymocyte globulin (ATG) in alternative donor transplants (n = 65); or alemtuzumab, fludarabine, total body irradiation 2 Gy (n = 12); or fludarabine, busulfan, cyclophosphamide, plus ATG in alternative donor transplants (n = 12) | ||||||
| bFludarabine, total body irradiation 2 Gy | ||||||
| cFludarabine, busulfan | ||||||
| dFludarabine, cyclophosphamide, rituximab plus ATG in alternative donor transplants | ||||||
| eFludarabine, busulfan, ATG | ||||||
| fDonors other than HLA-identical siblings | ||||||
| gEvent-free survival (counting graft rejection as event) | ||||||
| h“Current” PFS | ||||||
| jUpdated as of March 31, 2009 | ||||||
| kFludarabine, melphalan, alemtuzumab | ||||||
| n | 90 | 82 | 46 | 39 | 30 | 41 |
| Conditioning regimen | FC-based ± ATGa | F/TBI2b | FBc | FCR +/- ATGd | FB/ATGe | FM/CD52k |
| Proportion of alternative donorsf | 59% | 37% | 67% | 18% | 57% | 41% |
| 4-year progression-free survival | 42%g | 39% (5 y) | 34% (2 y) | 44%h | 58% | 45% (2 y) |
| 4-year overall survival | 70% | 50% (5 y) | 54% (2 y) | 48% | 69% | 51% (2 y) |
| 4-year non-relapse mortality | 21% | 23% (5 y) | 17% (2 y) | n.r. | 15% | 26% (2 y) |
| Extensive chronic GVHD | 52% | 49–53% | 38% | 58% | 21% | 5% |
| Median follow-up, y (range) | 3.1 (0.6–7.6)j | 5 | 1.7 | 2.3 (0.3–6.7) | 3.7 (2.1–5.6) | 1.3 (0–5.2) |
| . | Dreger et al16 . | Sorror et al15 . | Brown et al24 . | Khouri et al25 . | Schetelig et al13 . | Delgado et al36 . |
|---|---|---|---|---|---|---|
| aFludarabine, cyclophosphamide, plus anti-thymocyte globulin (ATG) in alternative donor transplants (n = 65); or alemtuzumab, fludarabine, total body irradiation 2 Gy (n = 12); or fludarabine, busulfan, cyclophosphamide, plus ATG in alternative donor transplants (n = 12) | ||||||
| bFludarabine, total body irradiation 2 Gy | ||||||
| cFludarabine, busulfan | ||||||
| dFludarabine, cyclophosphamide, rituximab plus ATG in alternative donor transplants | ||||||
| eFludarabine, busulfan, ATG | ||||||
| fDonors other than HLA-identical siblings | ||||||
| gEvent-free survival (counting graft rejection as event) | ||||||
| h“Current” PFS | ||||||
| jUpdated as of March 31, 2009 | ||||||
| kFludarabine, melphalan, alemtuzumab | ||||||
| n | 90 | 82 | 46 | 39 | 30 | 41 |
| Conditioning regimen | FC-based ± ATGa | F/TBI2b | FBc | FCR +/- ATGd | FB/ATGe | FM/CD52k |
| Proportion of alternative donorsf | 59% | 37% | 67% | 18% | 57% | 41% |
| 4-year progression-free survival | 42%g | 39% (5 y) | 34% (2 y) | 44%h | 58% | 45% (2 y) |
| 4-year overall survival | 70% | 50% (5 y) | 54% (2 y) | 48% | 69% | 51% (2 y) |
| 4-year non-relapse mortality | 21% | 23% (5 y) | 17% (2 y) | n.r. | 15% | 26% (2 y) |
| Extensive chronic GVHD | 52% | 49–53% | 38% | 58% | 21% | 5% |
| Median follow-up, y (range) | 3.1 (0.6–7.6)j | 5 | 1.7 | 2.3 (0.3–6.7) | 3.7 (2.1–5.6) | 1.3 (0–5.2) |